WO2024046512A3 - Nitrogen-containing macrocyclic compound, and preparation method therefor and medical use thereof - Google Patents

Nitrogen-containing macrocyclic compound, and preparation method therefor and medical use thereof Download PDF

Info

Publication number
WO2024046512A3
WO2024046512A3 PCT/CN2023/135839 CN2023135839W WO2024046512A3 WO 2024046512 A3 WO2024046512 A3 WO 2024046512A3 CN 2023135839 W CN2023135839 W CN 2023135839W WO 2024046512 A3 WO2024046512 A3 WO 2024046512A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrogen
preparation
method therefor
macrocyclic compound
medical use
Prior art date
Application number
PCT/CN2023/135839
Other languages
French (fr)
Chinese (zh)
Other versions
WO2024046512A2 (en
Inventor
沙汉明
齐旬通
张开清
张华洁
Original Assignee
中国医药研究开发中心有限公司
华润深圳湾发展有限公司科学技术研究分公司
深圳清华大学研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医药研究开发中心有限公司, 华润深圳湾发展有限公司科学技术研究分公司, 深圳清华大学研究院 filed Critical 中国医药研究开发中心有限公司
Publication of WO2024046512A2 publication Critical patent/WO2024046512A2/en
Publication of WO2024046512A3 publication Critical patent/WO2024046512A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a nitrogen-containing macrocyclic compound, and a preparation method therefor and the medical use thereof. Specifically, the present invention relates to a nitrogen-containing macrocyclic compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the use thereof as an ALK kinase inhibitor for treating diseases related to ALK kinase activity. The definition of each substituent in general formula (I) is the same as that in the description.
PCT/CN2023/135839 2022-12-01 2023-12-01 Nitrogen-containing macrocyclic compound, and preparation method therefor and medical use thereof WO2024046512A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211532795 2022-12-01
CN202211532795.1 2022-12-01

Publications (2)

Publication Number Publication Date
WO2024046512A2 WO2024046512A2 (en) 2024-03-07
WO2024046512A3 true WO2024046512A3 (en) 2024-04-18

Family

ID=90100461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/135839 WO2024046512A2 (en) 2022-12-01 2023-12-01 Nitrogen-containing macrocyclic compound, and preparation method therefor and medical use thereof

Country Status (1)

Country Link
WO (1) WO2024046512A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104169286A (en) * 2012-03-06 2014-11-26 辉瑞大药厂 Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (en) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 Macrocyclic compounds for the treatment of proliferative diseases
WO2021027503A1 (en) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 Tricyclic compound, preparation method therefor, and intermediate and use thereof
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
WO2021226269A1 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021226208A2 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2023179600A1 (en) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 Novel substituted macroheterocyclic compounds and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104169286A (en) * 2012-03-06 2014-11-26 辉瑞大药厂 Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (en) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 Macrocyclic compounds for the treatment of proliferative diseases
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
WO2021027503A1 (en) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 Tricyclic compound, preparation method therefor, and intermediate and use thereof
WO2021226269A1 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2021226208A2 (en) * 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2023179600A1 (en) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 Novel substituted macroheterocyclic compounds and use thereof

Also Published As

Publication number Publication date
WO2024046512A2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
MX2023012054A (en) Heterocyclic derivative inhibitor and preparation method therefor and application thereof.
MX2021006026A (en) Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof.
MX2022008881A (en) Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology.
MX2023007192A (en) Prmts inhibitors.
CR20220363A (en) Substituted tricyclic compounds
BR112022010254A2 (en) HETEROCYCLIC COMPOUND CONTAINING OXYGEN REPRESENTED BY FORMULA I, METHOD FOR PREPARING THE HETEROCYCLIC COMPOUND CONTAINING OXYGEN, COMPOUND, PHARMACEUTICAL COMPOSITION AND USE HETEROCYCLIC COMPOUND OXYGEN CONTAINING
MX2022013974A (en) Sos1 inhibitor containing phosphorus.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2023009222A (en) Tricyclic-amido-bicyclic prmt5 inhibitors.
MX2023007853A (en) Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof.
MX2022015531A (en) Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof.
MX2023006504A (en) Hydroxamate compound, preparation method therefor and application thereof.
MX2023007265A (en) Cdk inhibitors and their use as pharmaceuticals.
MX2022015679A (en) Tyk-2 inhibitor.
MX2023003576A (en) Compound as akt kinase inhibitor.
MX2022015813A (en) Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1.
MX2022007171A (en) Cyclic compounds and methods of using same.
CR20220538A (en) Compounds and compositions for inhibiting the activity of hif2-alpha and their methods of use
WO2022247920A9 (en) Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals
MX2021009971A (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2022016357A (en) Tetrazole derivatives as trpa1 inhibitors.
WO2024046512A3 (en) Nitrogen-containing macrocyclic compound, and preparation method therefor and medical use thereof
CR20210624A (en) Egfr inhibitor for the treatment of cancer
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23859538

Country of ref document: EP

Kind code of ref document: A2